ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,930.00
-40.00 (-0.80%)
At close: Apr 28, 2026
-6.63%
Market Cap 201.00B
Revenue (ttm) 56.67B
Net Income (ttm) -10.68B
Shares Out 40.77M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 101,993
Average Volume 115,979
Open 4,970.00
Previous Close 4,970.00
Day's Range 4,920.00 - 4,995.00
52-Week Range 4,410.00 - 6,350.00
Beta 0.67
RSI 53.58
Earnings Date n/a

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 178
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.